ProQR Therapeutics' (PRQR) "Market Outperform" Rating Reaffirmed at JMP Securities

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report)'s stock had its "market outperform" rating reaffirmed by equities researchers at JMP Securities in a report released on Friday,Benzinga reports. They currently have a $8.00 target price on the biopharmaceutical company's stock. JMP Securities' target price indicates a potential upside of 292.16% from the company's current price.

A number of other research firms also recently issued reports on PRQR. Citigroup upgraded ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a report on Monday, March 10th. Cantor Fitzgerald initiated coverage on shares of ProQR Therapeutics in a research report on Tuesday, April 29th. They set an "overweight" rating and a $8.00 price target for the company. Evercore ISI started coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 price objective on the stock. Oppenheimer lowered their target price on shares of ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Finally, HC Wainwright boosted their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Friday, March 14th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $8.00.

ProQR Therapeutics Stock Performance

Shares of NASDAQ PRQR remained flat at $2.04 during midday trading on Friday. 408,452 shares of the company traded hands, compared to its average volume of 654,349. ProQR Therapeutics has a one year low of $1.07 and a one year high of $4.62. The company has a market capitalization of $214.63 million, a price-to-earnings ratio of -5.83 and a beta of 0.31. The firm has a 50-day moving average of $1.74 and a 200-day moving average of $1.96.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The firm had revenue of $4.89 million for the quarter, compared to analysts' expectations of $4.90 million. ProQR Therapeutics had a negative return on equity of 53.49% and a negative net margin of 157.04%. Sell-side analysts predict that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PRQR. Jane Street Group LLC increased its position in shares of ProQR Therapeutics by 699.3% during the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company's stock valued at $121,000 after acquiring an additional 79,720 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in shares of ProQR Therapeutics by 16.3% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company's stock worth $4,368,000 after acquiring an additional 459,512 shares during the last quarter. Walleye Capital LLC grew its position in shares of ProQR Therapeutics by 11.6% during the 1st quarter. Walleye Capital LLC now owns 503,564 shares of the biopharmaceutical company's stock valued at $670,000 after acquiring an additional 52,261 shares during the period. Aberdeen Group plc bought a new stake in ProQR Therapeutics during the first quarter valued at about $2,461,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of ProQR Therapeutics during the 1st quarter valued at about $64,000. Institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).